News

Stephen R. Russell, MD, discussed the 9-year data he presented at the American Society of Retina Specialists annual meeting for voretigene neparvovec-rzyl.

Eastern Kentucky University student Madison Carlisle experienced rapid vision loss until the team at UK HealthCare was able to unravel the source of her issues.

Sadda is the second person to serve as chair. The first chairholder was John Irvine, MD, who was appointed to the role in 2001.

Technologies continue to push retina surgical suites into the future

The NIH-funded study finds lack of coverage, copays, restrictive policies barriers to vital eye care for adults.

According to the company, the priority review voucher would be issued upon approval of ATSN-201, a gene therapy product candidate.

US District Court Judge Anne Nardacci, presiding in the Northern District of New York, ruled David Kwiat, MD, and Kwiat Eye and Laser Surgery PLLC illegally retaliated against the employee based on protected activity.

Physicians share comprehensive approaches during roundtable discussion.

The Australian Society of Ophthalmologists hosted its inaugural Eye Surgery Showcase, where participants learned how ophthalmologists and the medical technology industry are working together to save the sight of Australians.

A team of researchers from Portugal and Belgium presented a paper highlighting the case of a patient with conjunctival CAM and offered an overview of the differential diagnosis and management of pigmented lesions of the conjunctiva.

Researchers noted that patients with sickle cell disease had an increased risk of developing any retinal vascular occlusion.

Current Fuchs endothelial corneal dystrophy treatments include implanted cultured human endothelial cells.

The authors explained that estimating the number of such visits in the US may help guide research and clinical efforts to optimize outcomes.

The FDA has a 60-day filing review period to determine whether the NDA submission is complete and acceptable for review.

According to the company, the FDA approval strengthens its biosimilar position in the US market.

Researchers conducted a retrospective cohort study that included adult patients 18 years and older who underwent primary repair of uncomplicated rhegmatogenous retinal detachment at the Wilmer Eye Institute from January 2008 to December 2018.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Researchers from the Shanghai Jiao Tong University School of Medicine developed a deep learning–based model for early identification of myopia, strabismus, and ptosis using 1419 facial photographs from 476 individuals.

The device features real-time feedback and other features, allowing residents to hone their skills and expand options for practicing one of the most needed procedures in the country.

Michael Abramoff, MD, PhD, a retina specialist and founder and executive chairman of Digital Diagnostics, points out that much evidence has been collected over the past few decades showing that early detection is key.

The agreement with give Apotex exclusive rights in Canada for the commercialization of APP13007.

LUBT010 is a ranibizumab biosimilar to Lucentis and the study achieved its primary endpoint

The program is for candidate OCU400, a modifier gene therapy product candidate.

The company hosted a virtual KOL event focusing on applicability and real-world experience with suprachoroidal drug delivery, the SCS as a differentiator in the retinal treatment landscape with a focus on wet AMD, and ongoing SCS clinical programs.

Kay Durairaj, MD, FACS, a facial plastic surgeon points out that the use of hyaluronidase in the periorbital region demands a meticulous approach due to the delicate anatomy and high risk of complications.

According to the company, the wearable smart glasses with both vision enhancement and assistance will be introduced at the American Retina Forum National Meeting

The Summit will feature 18+ course hours and an extensive resource library to support practice adoption of AT IOLs